<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00258232</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000445439</org_study_id>
    <secondary_id>P30CA022453</secondary_id>
    <secondary_id>WSU-C-2424</secondary_id>
    <nct_id>NCT00258232</nct_id>
  </id_info>
  <brief_title>Celecoxib, Capecitabine, and Irinotecan in Treating Patients With Recurrent or Metastatic Colorectal Cancer</brief_title>
  <official_title>Phase II Study of Celecoxib, Capecitabine, and Irinotecan in Patients With Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barbara Ann Karmanos Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Barbara Ann Karmanos Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Celecoxib may stop the growth of tumor cells by blocking some of the enzymes&#xD;
      needed for cell growth. Drugs used in chemotherapy, such as capecitabine and irinotecan, work&#xD;
      in different ways to stop the growth of tumor cells, either by killing the cells or by&#xD;
      stopping them from dividing. Giving celecoxib together with capecitabine and irinotecan may&#xD;
      kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving celecoxib together with capecitabine&#xD;
      and irinotecan works in treating patients with recurrent or metastatic colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the objective response rate in patients with locally recurrent or metastatic&#xD;
           colorectal cancer treated with celecoxib, capecitabine, and irinotecan.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the time to progression in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the toxicity of this regimen in these patients.&#xD;
&#xD;
        -  Determine the overall survival of patients treated with this regimen.&#xD;
&#xD;
        -  Determine the time to treatment failure in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive oral celecoxib twice daily on days -7 to 21 during course 1 and on days 1-21&#xD;
      in all subsequent courses. Patients also receive oral capecitabine twice daily on days 1-14&#xD;
      and irinotecan IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the&#xD;
      absence of disease progression or unacceptable toxicity. Patients achieving a complete or&#xD;
      partial response after 4 courses may temporarily discontinue treatment for no more than 4&#xD;
      weeks.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 6 months for survival.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 21-44 patients will be accrued for this study within 7-18&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2002</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate by RECIST criteria at every other course</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure</measure>
  </secondary_outcome>
  <condition>Colorectal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>celecoxib</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the colon or rectum&#xD;
&#xD;
               -  Locally recurrent or metastatic disease&#xD;
&#xD;
          -  Measurable disease, defined as ≥ 1 measurable lesion ≥ 20 mm by conventional CT scan&#xD;
             OR ≥ 10 mm by spiral CT scan&#xD;
&#xD;
               -  Bone metastases, ascites, and pleural effusion are not considered measurable&#xD;
                  disease&#xD;
&#xD;
               -  Measurable lesions must be located outside a previously irradiated field&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  SWOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  No Gilbert's disease&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine clearance &gt; 50 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No clinically significant cardiac disease that is not well controlled by medication,&#xD;
             including any of the following conditions:&#xD;
&#xD;
               -  Congestive heart failure&#xD;
&#xD;
               -  Symptomatic coronary artery disease&#xD;
&#xD;
               -  Cardiac arrhythmias&#xD;
&#xD;
          -  No myocardial infarction within the past year&#xD;
&#xD;
        Gastrointestinal&#xD;
&#xD;
          -  Must have a physically intact upper gastrointestinal tract&#xD;
&#xD;
          -  Able to swallow tablets&#xD;
&#xD;
          -  No history of peptic ulcer disease or gastroesophageal reflux&#xD;
&#xD;
          -  No malabsorption syndrome&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No known HIV positivity&#xD;
&#xD;
          -  No asthma, urticaria, or allergic-type reaction after prior treatment with aspirin or&#xD;
             other nonsteroidal anti-inflammatory drugs&#xD;
&#xD;
          -  No other malignancy except curatively treated cancer with no evidence of active&#xD;
             disease&#xD;
&#xD;
          -  No unresolved bacterial infection requiring antibiotics&#xD;
&#xD;
          -  No other serious infection&#xD;
&#xD;
          -  No known allergy to study drugs or sulfa drugs&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior chemotherapy for colorectal cancer&#xD;
&#xD;
               -  Patients relapsing &gt; 6 months after completion of prior adjuvant chemotherapy&#xD;
                  allowed&#xD;
&#xD;
          -  No other concurrent anticancer chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 3 weeks since prior radiotherapy&#xD;
&#xD;
          -  No concurrent anticancer radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Recovered from prior surgery&#xD;
&#xD;
          -  No concurrent anticancer surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Prior celecoxib for nonmalignant disorders allowed&#xD;
&#xD;
          -  No other concurrent cyclooxygenase-2 inhibitors or nonsteroidal anti-inflammatory&#xD;
             drugs, including any of the following:&#xD;
&#xD;
               -  Rofecoxib&#xD;
&#xD;
               -  Ibuprofen&#xD;
&#xD;
               -  Naproxen&#xD;
&#xD;
               -  Etodolac&#xD;
&#xD;
               -  Oxaprozin&#xD;
&#xD;
               -  Diflunisal&#xD;
&#xD;
               -  Nabumetone&#xD;
&#xD;
               -  Tolmetin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip A. Philip, MD, PhD, FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barbara Ann Karmanos Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0944</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201-1379</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210-1240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>El-Rayes BF, Venkat R, Heilbrun LK: A dose attenuated schedule of irinotecan and capecitabine in combination with celecoxib in advanced colorectal cancer. [Abstract] American Society of Clinical Oncology 2006 Gastrointestinal Cancers Symposium, 26-28 January 2006, San Francisco, California. A-254, 2006.</citation>
  </results_reference>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>November 22, 2005</study_first_submitted>
  <study_first_submitted_qc>November 22, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2005</study_first_posted>
  <last_update_submitted>April 5, 2013</last_update_submitted>
  <last_update_submitted_qc>April 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the colon</keyword>
  <keyword>adenocarcinoma of the rectum</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <keyword>stage IV colon cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

